# EDGAR Filing Document

**Accession Number:** 0001868912
**File Stem:** 0001558370-23-002043
**Filing Date:** 2023-2
**Character Count:** 4584
**Document Hash:** 8caa05cc77b766dc96056b46210597b2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001558370-23-002043.hdr.sgml**: 20230224

**ACCESSION NUMBER**: 0001558370-23-002043

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230223

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230224

**DATE AS OF CHANGE**: 20230224

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Enfusion, Inc.
- **CENTRAL INDEX KEY:** 0001868912
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-PREPACKAGED SOFTWARE [7372]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40949
- **FILM NUMBER:** 23667226

**BUSINESS ADDRESS:**
- **STREET 1:** 125 SOUTH CLARK STREET, SUITE 750
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60603
- **BUSINESS PHONE:** (312) 253-9800

**MAIL ADDRESS:**
- **STREET 1:** 125 SOUTH CLARK STREET, SUITE 750
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60603

?xml version='1.0' encoding='UTF-8'?

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT**

**TO SECTION 13 or 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): February 23, 2023**

## Enfusion, Inc.
**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40949** | **87-1268462** |
| (State or other jurisdiction<br>of Incorporation) | (Commission File Number) <br>| (I.R.S. Employer Identification No.) |

---

---

| | |
|:---|:---|
| **125 South Clark Street, Suite 750** | **60603** |
| **Chicago, Illinois** |  |
| (Address of principal executive offices) | (Zip code) |
| **(312) 253-9800** | **(312) 253-9800** |
| (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) |

---

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class** | **Name of each exchange**<br>**on which registered** |
| Class A common stock, par value $0.001 per share<br> ENFN | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

Effective February 23, 2023, Steven Bachert will no longer serve in the role of Chief Revenue Officer of Enfusion, Inc. Mr. Bachert's duties and responsibilities have been reassigned to existing management.

**Item 9.01 - Financial Statements and Exhibits.**

(d) The following exhibits are being filed herewith:

---

| | | |
|:---|:---|:---|
| **Exhibit No.** |  | **Description** |
| 104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: February 24, 2023 | **ENFUSION, INC.** | **ENFUSION, INC.** |
|  | By: | /s/ Matthew R. Campobasso |
|  | Name:  | Matthew R. Campobasso |
|  | Title: | General Counsel |

---